Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation

被引:49
作者
Cummins, N. W. [1 ,2 ]
Deziel, P. J. [2 ]
Abraham, R. S. [3 ]
Razonable, R. R. [1 ,2 ]
机构
[1] Mayo Clin, Coll Med, Dept Internal Med, Div Infect Dis, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, William J von Liebig Transplant Ctr, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Cellular & Mol Immunol Lab, Rochester, MN 55905 USA
关键词
cytomegalovirus; immunity; outcome; kidney transplantation; T cells; CD8+; late onset; LIVER-TRANSPLANTATION; ANTIVIRAL PROPHYLAXIS; RECIPIENTS; OUTCOMES; RISK; INFECTION; MORTALITY;
D O I
10.1111/j.1399-3062.2008.00344.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
N.W. Cummins, P.J. Deziel, R.S. Abraham, R.R. Razonable. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation.Transpl Infect Dis 2009: 11: 20-27. All rights reserved Cytomegalovirus (CMV) is a major cause of morbidity and mortality among transplant recipients. The routine use of anti-CMV prophylaxis has modified the epidemiology of post-transplant CMV infection by delaying the onset of clinical disease. While the majority of delayed-onset CMV disease still occurs during the first year after transplant, reports of late-onset CMV disease presenting many years after transplantation are increasing. Here, we describe 2 CMV-seropositive transplant recipients who presented with late-onset CMV disease at 8 and 11 years after transplantation. To determine whether CMV disease occurring at a very late period after transplantation is related to immune competence, we assessed global and CMV-specific cellular immunity by evaluating the activation capability of CD8+ T cells to a mitogenic stimulus and by quantitative and functional analysis (as assessed by intracellular cytokine production and degranulation) of CMV-specific CD8+ T cells. In both patients, we demonstrated the absence or marked deficiency of CMV-specific T-cell immunity despite CMV seropositivity, and in one patient, a partial defect in the immune response to phorbol myristate acetate and ionomycin suggesting impaired global immune competence. Hence, our data suggest that late-onset CMV disease occurring many years after transplantation remains related to defects in the immune competence of patients. Measurement of CMV-specific cellular immune competence may therefore provide an additional tool to screen for patients at high risk of developing late-onset CMV disease. The clinical utility of this assay, however, will need to be evaluated in larger prospective studies.
引用
收藏
页码:20 / 27
页数:8
相关论文
共 16 条
[1]   Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation [J].
Arthurs, Supha K. ;
Eid, Albert J. ;
Pedersen, Rachel A. ;
Kremers, Walter K. ;
Cosio, Fernando G. ;
Patel, Robin ;
Razonable, Raymund R. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (06) :840-846
[2]   Delayed-onset primary cytomegalovirus disease after liver transplantation [J].
Arthurs, Supha K. ;
Eid, Albert J. ;
Pedersen, Rachel A. ;
Dierichising, Ross A. ;
Kremers, Walter K. ;
Patel, Robin ;
Razonable, Raymund R. .
LIVER TRANSPLANTATION, 2007, 13 (12) :1703-1709
[3]   Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity [J].
Boeckh, M ;
Leisenring, W ;
Riddell, SR ;
Bowden, RA ;
Huang, ML ;
Myerson, D ;
Stevens-Ayers, T ;
Flowers, MED ;
Cunningham, T ;
Corey, L .
BLOOD, 2003, 101 (02) :407-414
[4]   Immunologic predictors of late cytomegalovirus disease after solid organ transplantation - An elusive goal? [J].
Boeckh, Michael ;
Riddell, Stanley R. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (05) :615-617
[5]   Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes [J].
Eid, Albert J. ;
Arthurs, Supha K. ;
Deziel, Paul J. ;
Wilhelm, Mark P. ;
Razonable, Raymund R. .
CLINICAL TRANSPLANTATION, 2008, 22 (02) :162-170
[6]   Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities [J].
Eid, Albert J. ;
Razonable, Raymund R. .
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2007, 12 (06) :610-617
[7]   Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients [J].
Humar, A ;
Mazzulli, T ;
Moussa, G ;
Razonable, RR ;
Paya, CV ;
Pescovitz, MD ;
Covington, E ;
Alecock, E .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (05) :1065-1070
[8]   Primary cytomegalovirus disease after five years of antiviral prophylaxis [J].
Kijpittayarit, S ;
Deziel, P ;
Eid, AJ ;
Razonable, RR .
TRANSPLANTATION, 2006, 81 (01) :137-138
[9]   Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients [J].
Kijpittayarit-Arthurs, Supha ;
Eid, Albert J. ;
Kremers, Walter K. ;
Pedersen, Rachel A. ;
Dierkhising, Ross A. ;
Patel, Robin ;
Razonable, Raymund R. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (10) :1019-1024
[10]   Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: Late-onset disease and indirect consequences [J].
Legendre, Christophe ;
Pascual, Manuel .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (05) :732-740